Story perspectives

Novo Nordisk Hit with Class-Action Suit Over Victoza Delays

1/25/2026

Summary

Story summary

Danish pharmaceutical company Novo Nordisk faces a New York class-action lawsuit alleging a pay-for-delay scheme to preserve its Victoza monopoly.
The suit centers on a Teva Pharmaceutical patent-litigation settlement that allegedly delayed the entry of a Victoza generic.
Smith Drug, the plaintiff, seeks unspecified damages for Victoza purchasers.
Analysts are divided on the stock's outlook, with some foreseeing a decline and others maintaining a buy rating.

1 of 1

Story summary

Danish pharmaceutical company Novo Nordisk faces a New York class-action lawsuit alleging a pay-for-delay scheme to preserve its Victoza monopoly.
The suit centers on a Teva Pharmaceutical patent-litigation settlement that allegedly delayed the entry of a Victoza generic.
Smith Drug, the plaintiff, seeks unspecified damages for Victoza purchasers.
Analysts are divided on the stock's outlook, with some foreseeing a decline and others maintaining a buy rating.